Dress syndrome secondary to simeprevir for the treatment of hepatitis c: A case report

• Autores: María Encina García Mayo, Silvia Vázquez Blanco, Ana Belén Veiga Villaverde, Carlos Crespo Diz
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 3, 2016, págs. 192-194
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The term Drug Reaction (rash) with Eosinophilia and Systemic Symptoms (DRESS) is used to describe a severe Adverse Drug Reaction (ADR) with a mortality rate of approximately 10%. Both the morphology of the skin lesions and the degree of systemic involvement vary among patients, and their onset implies the need to discontinue the suspected drug and administer corticotherapy. The present paper describes the case of a patient receiving treatment with simeprevir (SMV), pegylated interferon alpha-2a (PEG-INF) and ribavirin (RBV), who developed skin lesions, pruritus, rash, fever, eosinophilia, thrombocytopenia, lymphopenia, as well as frontal and periocular edemas, after 12 weeks of treatment. The patient was diagnosed with a DRESS syndrome based on regiSCAR (European Registry of Severe Cutaneous Adverse Reactions) criteria and on the skin biopsy performed. Treatment with topical corticoids was consequently initiated and SMV was subsequently discontinued, achieving gradual improvement of the patient’s clinical and haematological symptomatology